Verification of the performance of the BD MAX Check-Points CPO Assay on clinical isolates
- 주제(키워드) BD MAX Check-Points CPO Assay , carbapenemase , Enterobacteriaceae , real-time PCR
- 주제(기타) Medical Laboratory Technology
- 설명문(일반) [Chung, Hae-Sun; Lee, Miae] Ewha Womans Univ, Dept Lab Med, Coll Med, 25,Magokdong Ro 2 Gil, Seoul, South Korea
- 등재 SCIE, SCOPUS
- OA유형 gold
- 발행기관 WALTER DE GRUYTER GMBH
- 발행년도 2020
- 총서유형 Journal
- URI http://www.dcollection.net/handler/ewha/000000169148
- 본문언어 영어
- Published As https://dx.doi.org/10.1515/labmed-2019-0145
초록/요약
Objectives: The BD MAX Check-Points CPO Assay (BD MAX CPO Assay; BD, The Netherlands) is a diagnostic test designed for the rapid detection and differentiation of the bla(KPC), bla(NDM), bla(VIM)/bla(IMP-1),and bla(OXA-48) genes. We verified the performance of the BD MAX CPO Assay to implement it in the clinical laboratory. Methods: A total of 113 bacterial isolates collected from various clinical specimens harboring carbapenemase genes as confirmed by polymerase chain reaction (PCR) and sequencing were evaluated. The results of the BD MAX CPO Assay were compared to previously confirmed results. Results: All results of the BD MAX CPO Assay were concordant with previous results; 61 Klebsiella pneumoniae carbapenemase (KPC), 40 New Delhi metallo-beta-lactamase (NDM), three oxacillinase-48 (OXA-48)-like, two imipenem (IMP), and four multiple carbapenemase genes (one KPC/NDM, three NDM/OXA) were detected by the BD MAX CPO Assay. Three non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae isolates were negative. Conclusions: The BD MAX CPO Assay can be used to identify carbapenemase gene in bacterial isolates cultured from clinical specimens in the clinical laboratory.
more